Firms ally to create platform for immunotherapy production

03/27/2013 | Genetic Engineering & Biotechnology News · RTT News

Sanofi and Transgene will invest $12.9 million to create a new industrial platform for immunotherapy production. The platform will belong to Sanofi. Sanofi and Genzyme will use the platform to manufacture clinical and commercial batches of Transgene's MVA1 therapeutic vaccines and other immunotherapy products.

View Full Article in:

Genetic Engineering & Biotechnology News · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA